No Data
No Data
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today